Safety of mycophenolate mofetil monotherapy in patients after liver transplantation

Annals of Transplantation

Volumn 14, Issue 4, 2009, Pages 40-46

  Kamphues, Carsten ^a   Bova, Roberta ^a   Röcken, Christoph ^a   Neuhaus, Ruth ^a   Pratschke, Johann ^a   Neuhaus, Peter ^a   Neumann, Ulf P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Liver transplantation; Monotherapy; Mycophenolate mofetil

Indexed keywords

CYCLOSPORIN; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; ARTICLE; BONE MARROW; CREATININE BLOOD LEVEL; DIARRHEA; DRUG SAFETY; ENZYME BLOOD LEVEL; FAT CONTENT; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LEUKOCYTE; LIVER BIOPSY; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; VOMITING;

ADULT; BLOOD PLATELETS; CREATININE; FEMALE; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LEUKOCYTES; LIVER; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PATIENT SELECTION; RETROSPECTIVE STUDIES;

EID: 74949094196     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Williams JW, Vera SR, Peters TG, Van Voorst S: Survival following hepatic transplantation in the cyclosporine era. Ann Surg, 1986; 52: 291
2. Platz KP, Müller AR, Blumhardt G: Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporine and FK 506. Transplantation, 1994; 58: 170-78
3. Ojo AO. Held PJ. Port FK et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 2003; 349: 931-40
4. Paramesh AS, Roayale S, Doan Y et al: Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant, 2004; 18: 94
5. Gonwa TA, Mai ML, Melton LB et. al: End-stage renal disease (ESRD) after orthtopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Transplantation, 2001; 72: 1934-39
6. Lee WA, Gu L, Miksztal AR et al: Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res, 1990; 7: 161
7. Lipsky JL: Mycophenolate mofetil. Lancet, 1996; 348: 1357
8. Bahra M, Neumann UP, Jacob D et al: MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant, 2005; 5: 406
9. Monsour HP, Wood RP, Dyer CH et al: Renal insufficiency and hypertension as longterm complications in liver transplantation. Semin Liver Dis, 1995; 15: 123
10. Stewart SF, Hudson M, Talbot D et al: Mycophenolate mofetil monotherapy in liver transplantation. Lancet, 2001; 357: 609-11
11. Schlitt HJ, Barkmann A, Böker KH et al: Replacement of calcineurin inhibitors with myc-ophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancer 2001; 357: 587-91
12. Raimondo ML, Dagher L, Papatheodoridis GV et al: Long-term mycophenolate mofetil in combination will calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation, 2003; 75: 186-90
13. Moreno JM, Cuervas-Mons V, Rubio E et. al: Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant, 2004; 4: 1650-55
14. Koch RO, Gaziadei IW, Schulz F et al: Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin-induced renal dysfunction. Transplant Int, 2004; 17: 518-24
15. Orlando G, Baiocchi L, Cardillo A et al: Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia and hypertension. Liver Transpl, 2007; 13: 46-54
16. Pageaux GP, Rostaing L, Calmus Y et al: Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl, 2006; 12: 1755-60
17. Schmeding M, Neumann UP, Neuhaus R, Neuhaus P: Mycophenolate mofetil in liver transplantation - is monotherapy safe? Clin Transplant, 2006; 20(Suppl.17): 75-79
18. Bilbao I, Castells L, Rojas L et al: Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. International Immunopharmacology, 2006; 6: 1977-83
19. Créput C, Blandin F, Deroure B et al: Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl, 2007; 13: 1004-10
20. Demetris AJ, Adams B. Bellamy C et al: Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology, 2000; 31(3): 792-99
21. Vauthey JN, Pawlik TM, Ribero D et al: Chemotherapy, regimen predicts steatohepatitis and an increase in 90-day mortality after surgery heaptic colorectal metastases. J Clin Oncol, 206; 24: 2065-72
22. Pierini A, Mirabella S, Brunati A et al: Mycophenolate mofetil monotherapy in liver transplantation. Transpl Proc, 2005; 37: 2611-15